Syncona Corporate Presentation

August 2020

synconaltd.com Image Freeline labs, Stevenage

Cautionary statement

This presentation has been prepared and published solely for informational purposes. Nothing contained in this presentation is intended to constitute an offer, invitation or inducement to engage in an investment activity.

In this statement, "presentation" means this document together with any oral presentation, any question or answer session and any written or oral material discussed or distributed during the meeting.

In making this presentation available, Syncona Ltd makes no recommendation to purchase, sell or otherwise deal in shares in Syncona Ltd or any other securities or investments and you should neither rely nor act upon, directly or indirectly, any of the information contained in this presentation in respect of such investment activity. This presentation has not been approved by an authorised person or by any supervisory or regulatory authority.

This presentation speaks as of its date and the information and opinions it contains are subject to change without notice. Neither Syncona Ltd nor its affiliates, agents, directors, managers and advisers (together "representatives") are under any obligation to update or keep current the information contained in this presentation.

The information and opinions contained in the presentation do not purport to be comprehensive. This presentation has not been independently verified. No representation, warranty or other assurance, express or implied, is or will be made in relation to, and no responsibility is or will be accepted by Syncona Ltd or its representatives as to the accuracy, correctness, fairness or completeness of, the information or opinions contained in this presentation. Syncona Ltd and its representatives accept no liability whatsoever for any loss or damage howsoever arising from any use of this presentation or its content or otherwise arising in connection with it.

The presentation may contain "forward-looking statements" regarding the belief or current expectations of Syncona Ltd and its representatives about the financial condition, results of operations and business of Syncona Ltd and its portfolio of investments. Such forward-looking statements are not guarantees of future performance. Rather, they speak only as of the date of this presentation, are based on current views and assumptions and involve known and unknown risks, uncertainties and other factors, many of which are outside the control of Syncona Ltd and are difficult to predict, that may cause the actual results, performance, achievements or developments of Syncona Ltd, its current or future investments or the industry in which it operates to differ materially from any future results, performance, achievements or developments expressed or implied from the forward-looking statements. In particular, many companies in the Syncona Ltd portfolio are conducting scientific research and clinical trials where the outcome is inherently uncertain and there is significant risk of negative results or adverse events arising. In addition, many companies in the Syncona Ltd portfolio have yet to commercialise a product and their ability to do so may be affected by operational, commercial and other risks.

The target return of Syncona Ltd referred to in this presentation is based on performance projections produced by Syncona Ltd and its representatives to the best of their knowledge and belief. It is a target only and therefore subject to change. There is no guarantee that such target return of Syncona Ltd can be achieved and past or targeted performance is no indication of current or future performance or results. There can be no assurance that the strategy described in this presentation will meet its objectives generally, or avoid losses.

This presentation is not for publication, release or distribution, directly or indirectly, in nor should it be taken or transmitted, directly or indirectly into, any other jurisdiction where to do so would constitute a violation of the laws of that jurisdiction. The distribution of this presentation outside the United Kingdom may be restricted by law and therefore persons outside the United Kingdom into whose possession this presentation comes should inform themselves about and observe any such restrictions as to the distribution of this presentation.

Strategy and vision

Building the next generation of healthcare leaders

Capturing the out-return from commercialising exceptional science

Globally significant scientific research base

Leverage the quality of the European life science research base

01

Focus on products and patients

Select technology that can:

  • deliver dramatic efficacy for patients

  • credibly be taken to approval by an innovative biotech

02

Founding companies with strategic ownership

Invest through company life cycle to maintain significant ownership positions, enabling:

  • strategic influence; leveraging expertise in Syncona team

  • participation in the out return available from taking products to approval

03

Long-term, ambitious capital

Fund ambitiously over time frames necessary to develop innovative medicines

04

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Syncona Ltd. published this content on 28 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 September 2020 15:24:05 UTC